However, a very recent study has suggested that flecainide does not inhibit luminal-to-cytosolic cation flux through RyR2 and that the drug's beneficial actions in CPVT are secondary to Na+-dependent modulation of intracellular Ca2 + ion handling [61]. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.